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Acquired Isodisomy on Chromosome 13 at diagnosis results in impaired overall survival in Patients 1 
with FLT3-ITD mutant Acute Myeloid Leukaemia 2 
Internal tandem duplication (ITD) mutations in the FLT3 gene on chromosome 13 occur in 25% of 3 
patients with acute myeloid leukaemia (AML) and result in impaired overall survival.(1) Patients with 4 
a high allelic ratio (AR) of ITD mutant to wildtype FLT3 in genomic DNA have an even poorer 5 
prognosis.(2) AR may be a predictor of response to FLT3 inhibitors(3) and may also interact with 6 
other mutations in influencing disease risk.(4, 5) 7 
AR may be dependent on a number of factors including loss of the wildtype allele.  Acquired 8 
isodisomy (AID) results in the loss of the wildtype allele, through duplication of the mutant allele 9 
with segmental loss of the wildtype allele.  Although studies(6) have shown the importance of AID at 10 
chromosome 13 (AID13) at relapse, the impact of AID13 at diagnosis is unclear.  This study aimed to 11 
identify the relationship between AID13 and FLT3-ITD AR and investigated the outcomes of patients 12 
with AID13.   13 
All patients diagnosed with AML underwent FLT3 mutation analysis in the West Midlands Regional 14 
genetics laboratory between 2002 and 2015 and are included in this study. FLT3 and NPM1 mutation 15 
analysis by PCR of genomic DNA was undertaken as described.(7)  PCR products were identified 16 
using fluorescent based fragment analysis (Applied Biosystems, US).  Allelic ratio (AR) (mutation: wild 17 
type ratio in genomic DNA) was determined from the relative peak heights.  AID was determined by 18 
analysis of microsatellite markers along chromosome 13 in patients with AR above 0.25 (8)  19 
(supplementary figure 1). 20 
Complete remission (CR), event-free survival (EFS) and overall survival (OS) were defined as 21 
described.(9)   OS and EFS were estimated by the Kaplan-Meier method.  Survival curves were 22 
compared using the log rank test.  Variables were compared using Wilcoxon or chi-squared test as 23 
appropriate.  Statistical analyses were performed with R 3.0.3, and the R-packages ‘survival’ and 24 
SPSS (version 19).   25 
Two hundred and eighty-nine patients diagnosed with FLT3-ITD mutated AML are described 26 
(Supplementary Table 1).  The median age at diagnosis was 61 years.  Of 280 patients tested, 45% 27 
had the NPM1 exon 12 mutation. Cytogenetic classification by MRC criteria (10) showed 77% of 267 28 
patients were of intermediate risk.  29 
We investigated which factors influenced allelic ratio (AR). The first was the loss of the wildtype 30 
allele.  Loss of the wildtype allele can occur through the loss of all or part of chromosome 13 but was 31 
seen in only 3 patients. The most frequent mechanism for the loss of the wildtype allele is the 32 
presence of AID13; this was seen in 12.8% (n=34/266) of patients with FLT3-ITD AML at diagnosis. 33 
AID13 was associated with a significant increase in AR (Wilcoxon test p<0.0001, supplementary 34 
figure 2a).  However, AR is an imperfect surrogate for loss of the wildtype allele as 2 patients with 35 
AID13 had an AR less than 0.5, and conversely, 106 patients with an AR over 0.5 did not have AID13.  36 
AID13 itself was associated with an increased white cell count, which was not statistically significant 37 
(Wilcoxon test: p=0.096) (supplementary figure 2b).  AID13 was significantly associated with an 38 
intermediate cytogenetic risk profile and the presence of a NPM1 mutation (chi-squared: p<0.05) 39 
(supplementary figure 2c).   40 
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AR is also thought to be associated with the size of ITD, and the presence of contaminating normal 41 
cells.  Therefore, we also investigated the relationship between these factors and AR.  There was no 42 
association between AR and ITD size.  The presence of contaminating cells is inversely correlated 43 
with the percentage of blasts in the sample.  Although the association between AR and blast 44 
percentage was statistically significant, the correlation was very weak (Pearson’s correlation 45 
coefficient +0.154 (p=0.02)) (Supplementary figure 3 a) and b)).  Having accounted for these other 46 
factors, this suggests AID13 is the key factor affecting AR. 47 
Outcomes were analysed for 179 patients treated with curative intent who did not have APML. The 48 
majority of these patients were treated on the concurrent national AML cooperative trials, with a 49 
standard combination of anthracyclines and cytarabine (supplementary table 1).  Patients obtained 50 
CR independent of AID13 or AR level (supplementary figure 4a and b).  An AR level of 0.5 to split the 51 
patient population was based on its use in previous studies (2, 4, 5).  Post-remission outcome is 52 
strongly influenced by choice of consolidation treatment, in particular allogeneic stem cell transplant 53 
(SCT).  To understand the influence of AR and AID13 on outcomes and the role for SCT in the 54 
management of these patients we stratified time-event analysis based on whether patients received 55 
SCT or chemotherapy only. 56 
In patients treated with chemotherapy alone, an AR ≥0.5 was compared to an AR <0.5. A high AR 57 
conferred a worse prognosis in both EFS (p=0.023) and OS (p=0.039) (figure 1a).  In the same 58 
patients, the presence of AID13 also conferred a worse prognosis in EFS (p=0.057) and OS (p=0.029) 59 
(figure 1b).  Because AID13 increases the AR, it is important to understand the relative contribution 60 
of AID13 to a high AR.  High AR patients were therefore stratified into those with and without AID13.  61 
The poor prognostic impact of AR≥0.5 was no longer significant when AID13 patients were not 62 
included, measured by both EFS (AR≥0.5 without AID13 vs AR<0.5 p=0.064) and OS (AR≥0.5 without 63 
AID13 vs AR<0.5 p=0.119). 64 
Of the 179 non-APML patients treated with curative intent, 70 received a SCT (supplementary table 65 
3).  High AR (≥0.5) did not have a poor prognostic impact in the SCT treated patients (EFS: p=0.477; 66 
OS: p=0.669), supplementary figure 5a).  Similarly, AID13 did not confer a poor prognostic impact in 67 
patients treated with SCT (EFS: p=0.663; OS: p=0.536), supplementary figure 5b). There was also no 68 
impact from a high AR (≥0.5) in patients without AID13 treated with SCT, as seen with those treated 69 
without SCT (EFS: p=0.281; OS: p=0.823, supplementary figure 5c). 70 
Of the 70 SCT treated patients, 28 (40%) remain alive.  17 of the 70 had AID13, and, of these, 6 71 
remain alive. 11 died, 6 from relapse and 5 from NRM.  7 out of 8 patients with AID treated with 72 
intensive chemotherapy alone died with active disease.  This suggests that SCT may ameliorate the 73 
poor risk of AID13. 74 
AID has been a common finding at relapse.(6)  Of 45 patients who had sequential relapsed bone 75 
marrow samples, 5 developed AID13 as a new finding.  6 relapsed with a FLT3-ITD negative clone, 76 
consistent with data that it is a secondary driver mutation.(11) Consistent with AID13 being a driver 77 
of relapse, in 5 out of 6 patients with AID13 with available relapse data there was no loss of AID13 at 78 
relapse.  79 
In summary, we show that AID13 at diagnosis is associated with impaired overall survival in patients 80 
who are treated with chemotherapy alone, and that this is the major part of the effect of a high AR. 81 
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A smaller study (12) also used microsatellite markers to investigate the impact of AID13, and 82 
suggested that AID13 resulted in a decreased OS.  The frequency of AID13 in our study of 83 
consecutive patients (12.8%) was lower than that described by this smaller study (8/23 patients, 84 
34%). The frequency of AID13 at an intermediate mutant level (0.25-0.5) was low in our study (1/60). 85 
Another study (13) identified only 2 of 34 patients with AID13 using single nucleotide polymorphism 86 
arrays, confirming this result. 87 
This study has demonstrated the poor prognosis of patients with AID13 or a high AR in patients 88 
treated with chemotherapy alone. The poor outcomes were ameliorated in those who received SCT. 89 
Our data is consistent with a prospective study from the German Austrian AML Study group who 90 
showed an SCT improved OS compared to intensive chemotherapy alone in patients with FLT3-ITD 91 
with a high AR, but no benefit was seen in those with a low AR.(2)  92 
Several studies have implicated the AR of FLT3-ITD as an important factor in determining the 93 
outcomes of patients with this mutation.(1, 3-5)  This study suggests mitotic recombination leading 94 
to AID13 is a major mechanism of increasing the allelic ratio of FLT3-ITD.  Importantly, it is 95 
detectable by an accessible laboratory assay with a binary outcome.  In contrast to allelic ratio, 96 
which is a continuous variable.  Our data demonstrates differences in the outcomes of patients with 97 
AID13 suggesting patients with heterozygous and homozygous FLT3-ITD mutations are distinct 98 
cohorts.  This is consistent with murine models where homozygous FLT3-ITD mutation results in a 99 
more severe myeloproliferative phenotype than those with either a heterozygous (14) or 100 
hemizygous mutation.(15) The loss of the wildtype allele is also important, as seen in FLT3-ITD 101 
hemizygous cells which show a more aggressive phenotype than the heterozygous cells, which retain 102 
the wildtype copy of FLT3.(15) AID13 is a single event which results in both a gain of a second FLT3-103 
ITD allele and the loss of the wildtype allele.  104 
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Figure Legends 136 
1) Figure 1 Event free survival (EFS) and overall survival (OS) based on allelic ratio (AR) and 137 
acquired isodisomy at chromosome 13 (AID13) stratification for patients treated with 138 
intensive chemotherapy alone 139 
a) EFS and OS for AR ≥0.5 vs AR<0.5 140 
b) EFS and OS for presence or absence of AID13 141 
c) EFS and OS for AR ≥0.5 without AID13 vs AR<0.5 142 
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